Wegovy Patient Support - Important Information
Welcome to Wegovy Patient Support. Our goal is to provide you with vital information to ensure a comprehensive understanding of Wegovy, its uses, and its significance in medical treatment.
Medication Overview
- 1) Wegovy: This medication is manufactured by the pharmaceutical company Novo Nordisk and contains the active substance semaglutide. Wegovy is a unique drug designed specifically for the treatment of obesity.
Understanding Wegovy
- 1) Introduction: Launched by Novo Nordisk on 4th September 2023, Wegovy represents a significant advancement in medical treatment. It contains semaglutide and is exclusively licensed for addressing obesity.
Navigating the Transition
The transition from Ozempic being used off-label for obesity to the introduction of Wegovy marks a crucial development in medical care. Novo Nordisk's dedication to tackling obesity is evident through the specialized licensing of Wegovy for this purpose.
If you have any questions, concerns, or need further information about Wegovy or its usage, please feel free to reach out to our support team. We are here to assist you on your journey towards better health.